Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 2/20 | 0.57 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.57 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.57 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | GLP1R | P43220 | 1/20 | 0.53 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30262251 | 0.92 | TFPI (0.63) | TFPIF2VIPR2VIPR1IL23R | |
| SCHEMBL29686242 | 0.89 | KISS1R (0.62) | TFPIF2VIPR2VIPR1 | |
| SCHEMBL29742337 | 0.89 | TFPI (0.58) | TFPIF2VIPR2VIPR1IL23R | |
| SCHEMBL31437676 | 0.89 | NPY4R (0.60) | TFPIVIPR2VIPR1 | |
| SCHEMBL30176441 | 0.89 | TFPI (0.64) | TFPIKEAP1VIPR2VIPR1ECE1 | |
| SCHEMBL30220503 | 0.89 | TFPI (0.66) | TFPIKEAP1VIPR2VIPR1ECE1 | |
| SCHEMBL30168722 | 0.89 | TFPI (0.59) | TFPIF2VIPR2VIPR1IL23R | |
| SCHEMBL19221753 | 0.88 | TFPI (0.59) | TFPIF2IL23R | |
| SCHEMBL30900764 | 0.88 | TFPI (0.65) | TFPIVIPR2VIPR1ECE1GLP1R | |
| SCHEMBL30900785 | 0.88 | TFPI (0.65) | TFPIVIPR2VIPR1ECE1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230464-A2 | A MURINE MODEL TO TEST THE EFFECT OF PKP2 MUTATIONS ON LIVING ADULT HEARTS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2023-11-30 | — | — | WO | claimed |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | AUCKLAND UNISERVICES LTD (NZ) | 2026-04-02 | — | — | US | disclosed |
| EP-4677087-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | Glaukos Corporation (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | INFLAMMX THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250136987-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250127851-A1 | CYTOKINE MODULATION | INFLAMMX THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12226393-B2 | Neuroprotective compounds for amyotrophic lateral sclerosis | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4491184-A2 | CHANNEL MODULATORS | Auckland Uniservices Limited (NZ) | 2025-01-15 | — | — | EP | disclosed |
| EP-3183346-B1 | CHANNEL MODULATORS | AUCKLAND UNISERVICES LTD (NZ) | 2024-10-23 | — | — | EP | disclosed |
| US-20240299440-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | GLAUKOS CORPORATION | 2024-09-12 | — | — | US | disclosed |
| US-11717506-B2 | Neuroprotective compounds for amyotrophic lateral sclerosis | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230174980-A1 | CHANNEL MODULATORS | INFLAMMX THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230123615-A1 | METHODS OF TREATMENT AND NOVEL CONSTRUCTS | INFLAMMX THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-11466069-B2 | Methods of treatment and novel constructs | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-10-11 | — | — | US | disclosed |
| US-20220288163-A1 | CYTOKINE MODULATION | INFLAMMX THERAPEUTICS, INC. | 2022-09-15 | — | — | US | disclosed |
| US-11401516-B2 | Channel modulators | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-08-02 | — | — | US | disclosed |
| US-11344603-B2 | Cytokine modulation | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-05-31 | — | — | US | disclosed |
| EP-3958886-A1 | COMPOSITIONS AND METHODS FOR PROTECTING EPITHELIAL AND BARRIER INTEGRITY | Ocunexus Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114010788-A | Channel modulators | 奥克兰联合服务有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-114025786-A | Compositions and methods for protecting epithelial and barrier integrity | 欧耐柯萨斯医疗有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174980-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | TFPI 2323/4885KEAP1 1638/4885F2 4487/4885 |
| US-20240299440-A1 | NOVEL TREATMENTS FOR OCULAR DISORDERS | GJB2, GJA1, CX3CR1 | TFPI 3415/4885KEAP1 1593/4885F2 4503/4885 |
| US-20260091017-A1 | TREATMENTS FOR INFLAMMATION | P2RX7, NLRP3, PYCARD | TFPI 293/4885KEAP1 541/4885F2 3755/4885 |
| US-20250352508-A1 | PREVENTION AND TREATMENT OF POST-ACUTE INFECTION SYNDROMES | NLRP3, GJA1, PYCARD | TFPI 1780/4885KEAP1 433/4885F2 3585/4885 |
| US-11717506-B2 | Neuroprotective compounds for amyotrophic lateral sclerosis | NLN, SMN1; SMN2, SOD1 | TFPI 3000/4885KEAP1 445/4885F2 4780/4885 |
| US-12226393-B2 | Neuroprotective compounds for amyotrophic lateral sclerosis | NLN, SMN1; SMN2, SOD1 | TFPI 3000/4885KEAP1 445/4885F2 4780/4885 |
| US-20250127851-A1 | CYTOKINE MODULATION | TNF, IL2, IL1B | TFPI 1618/4885KEAP1 3047/4885F2 3537/4885 |
| US-20220288163-A1 | CYTOKINE MODULATION | TNF, IL2, IL1B | TFPI 1618/4885KEAP1 3047/4885F2 3537/4885 |
| US-11401516-B2 | Channel modulators | GJB2, GJA1, P2RX2 | TFPI 2323/4885KEAP1 1638/4885F2 4487/4885 |
| US-11344603-B2 | Cytokine modulation | TNF, IL2, IL1B | TFPI 1618/4885KEAP1 3047/4885F2 3537/4885 |
| US-20250136987-A1 | CHANNEL MODULATORS | GJB2, GJA1, P2RX2 | TFPI 2323/4885KEAP1 1638/4885F2 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.